Saroja Pharma Industries India Limited (NSE:SAROJA)

Revenue by Segment

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Pharmaceutical Business		537.27M	406.69M	501.93M	556.33M	366.62M
Pharmaceutical Business Growth		32.11%	-18.97%	-9.78%	51.75%	114.65%
Total		537.27M	406.69M	501.93M	556.33M	366.62M
Total Growth		32.11%	-18.97%	-9.78%	51.75%	114.65%

Revenue by Geography

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
India		491.69M	336.21M	450.03M	434.58M	312.46M
India Growth		46.25%	-25.29%	3.56%	39.08%	-
Asia Pacific		45.58M	60.11M	46.63M	-	-
Asia Pacific Growth		-24.18%	28.92%	-	-	-
Europe		-	9.35M	459.00K	-	-
Europe Growth		-	1936.60%	-	-	-
Rest of The World		-	1.03M	-	-	-
Pakistan		-	-	-	91.55M	45.18M
Pakistan Growth		-	-	-	102.66%	-
Jordan		-	-	-	9.97M	3.76M
Jordan Growth		-	-	-	165.20%	-
Hong Kong		-	-	-	3.52M	4.49M
Hong Kong Growth		-	-	-	-21.66%	-
Singapore		-	-	-	1.34M	-
Russia		-	-	-	4.08M	-
Egypt		-	-	-	7.76M	-
Ghana		-	-	-	459.00K	414.00K
Ghana Growth		-	-	-	10.87%	-
Uruguay		-	-	-	818.00K	224.00K
Uruguay Growth		-	-	-	265.18%	-
United Kingdom		-	-	-	1.06M	90.00K
United Kingdom Growth		-	-	-	1076.67%	-
Netherland		-	-	-	1.19M	-
Total		537.27M	406.69M	497.12M	556.33M	366.62M
Total Growth		32.11%	-18.19%	-10.64%	51.75%	-

Source: S&P Global Market Intelligence.